Beyond Moderna's Regulatory Legacy (Re)defining The mRNA Reg

It’s unlikely we will need to burn nearly as much “midnight oil” as Moderna and the regulatory bodies did during the pandemic.

Related Keywords

Chris Kelly , Anna Rose Welch , Rna Process Development , Office Of Therapeutic Products , Manufacturing Summit , Global Director , Therapeutic Products ,